Viral Vector Manufacturing Market Research Report 2023-2028

Author: Elena Anderson, Marketing Manager |

Group

Report DescriptionAbout IMARC Group

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Global Viral Vector Manufacturing Market Research Report:

A viral vector is a tool deployed by molecular biologists to deliver genetic materials into cells. It is widely employed in cell and gene therapy to substitute defective genes for curing genetic disorders. It also expresses and presents pathogenic antigens by mimicking a natural infection for developing an immune response. In addition, it is used in treating various diseases, such as metabolic diseases, heart defects, neurodegenerative disorders, and oncolytic therapies to target and kill tumor cells. At present, viral vector manufacturing finds applications in gene therapy, life science research, and vaccinology across the globe.

Viral Vector Manufacturing Market Trends and Drivers:

The market is primarily driven by the growing prevalence of chronic diseases such as genetic disorders, cancer, and infectious diseases. In addition, the increasing consumption of alcohol due to the sedentary lifestyles of individuals is contributing to the market growth. Moreover, as viral vectors are efficient carriers of virus-disabling sequences, they are widely used to provide HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs), which represents another major growth-inducing factor.

Report Description Report Description and Highlights

Besides this, the increasing inclination toward clinical studies undertaken on viral vectors and the growing use of viral vectors in novel drug delivery is propelling the market growth. Along with this, governments are launching campaigns to create awareness regarding viral vector vaccines among individuals and improving the regulatory environment through changes that are accelerating the product adoption rate.

Furthermore, extensive research and development (R&D) activities and mergers and acquisitions (M&A) among key players to increase their overall sales and profitability are influencing the global market outlook.

Request a Free PDF Sample for more detailed market

insights: https://www.imarcgroup.com/viral-vector-manufacturingmarket/requestsample

Report Description Report Description and Highlights

Global Viral Vector Manufacturing Market 2022-2027 Analysis and Segmentation: Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi

S.A., Thermo Fisher Scientific Inc. and uniQure N.V.

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/viral-vector-manufacturing-market

Report Description Report Description and Highlights

The report has segmented the market on the basis of region, type, disease, application and end user.

Breakup by Type:

Adenoviral Vectors

Adeno-associated Viral Vectors

Lentiviral Vectors

Retroviral Vectors • Others

Breakup by Disease:

Cancer

Genetic Disorders

Infectious Diseases

Others

Report Description Report Description and Highlights

Breakup by Application:

Gene Therapy

Vaccinology

Breakup by End User:

Pharmaceutical and Biopharmaceutical Companies

Research Institutes

Breakup by Region:

North America: (United States, Canada)

Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)

Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

Latin America: (Brazil, Mexico, Others)

Middle East and Africa

Report Description Report Description and Highlights

If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.

Key highlights of the report:

Market Performance (2016-2021)

Market Outlook (2022- 2027)

Porter’s Five Forces Analysis

Market Drivers and Success Factors

SWOT Analysis

Value Chain

Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

Report Description Report Description and Highlights

© 2019 IMARC All Rights Reserved

This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.